KR910004609A - 아미노케톤 유도체 및 그의 용도 - Google Patents

아미노케톤 유도체 및 그의 용도 Download PDF

Info

Publication number
KR910004609A
KR910004609A KR1019900011987A KR900011987A KR910004609A KR 910004609 A KR910004609 A KR 910004609A KR 1019900011987 A KR1019900011987 A KR 1019900011987A KR 900011987 A KR900011987 A KR 900011987A KR 910004609 A KR910004609 A KR 910004609A
Authority
KR
South Korea
Prior art keywords
group
lower alkyl
physiologically acceptable
acceptable salt
derivative according
Prior art date
Application number
KR1019900011987A
Other languages
English (en)
Other versions
KR920009062B1 (ko
Inventor
아끼라 마쓰바라
가즈야 사까이
히데끼 다나다
아끼라 미즈찌
가즈또시 호리꼬미
히데시 시미즈
Original Assignee
사와무라 하루오
미쓰이도오아쓰가가꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사와무라 하루오, 미쓰이도오아쓰가가꾸 가부시끼가이샤 filed Critical 사와무라 하루오
Publication of KR910004609A publication Critical patent/KR910004609A/ko
Application granted granted Critical
Publication of KR920009062B1 publication Critical patent/KR920009062B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

내용 없음.

Description

아미노케톤 유도체 및 그의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 하기 일반식 (I)으로 표시되는 아미노 케톤 유도체.
    식중, R1은 또는이고 (식중, R6할로겐 원자, 저급 알킬기, 벤질기, 벤조일기, 피리딜기; 하나 이상의 저급 알킬기로 임의로 치환될 수 있는 푸릴기; 하나 이상의 저급 알킬기로 임의로 치환될 수 있는 티엔일기; 하나 이상의 할로겐 원자 및/또는 하나 이상의 저급 알콕시, 저급 알킬, 트리플루오로메틸, 시아노, 니트로, 아미노, 디메틸아미노, 아세트아미도, 메탄술포닐아미도, 아세틸 및/또는 저급 알콕시카르보닐기로 임의로 치환될 수 있는 페닐기, 또는 나프틸기 이고, R7및 R8은 독립적으로 페닐 또는 저급 알킬기이며, Z는 산소 또는 황 원자이다.) ; R2는 수소원자, 저급알킬, 벤질, 메톡시, 페닐, 알릴, 트리플루오로메틸- 또는 저급 알콕시- 치환 저급 알킬, 또는 시클로프로필메틸기를 나타내며, R3은 수소 원자 또는 저급 알킬기이거나, R2및 R3는 함께 결합되어 5원 또는 6원 지방족 고리형 기를 형성하고; R4및 R5는 독립적으로 포화 또는 불포화 저급 알킬기를 나타내거나, R4및 R5는 함께 고리형으로 결합되어 피롤리딘, 피페리딘, 헥사메틸렌이미드, 모르폴린 및 피레라진 구조로 이루어지는 군에서 선택된 적어도 하나의 고리형 구조를 형성하며, 상기 고리형 구조는 하나 이상의 메틸, 아세틸 및 벤질기에 의해 일의로 치환될 수 있다.
  2. 제1항에 따르는 아미노케톤 유도체의 생리학적으로 허용되는 염.
  3. 제1항에 따르는 아미노케톤 유도체 또는 그의 생리학적으로 허용되는 염을 유효 성분으로서 함유하는 중추계 작용 근육 이완제.
  4. 제1항에 따른 아미노케톤 유도체 또는 그의 생리학적으로 허용되는 염을 유효성분으로서 함유하는 요의 빈삭치료제.
  5. 제1항에 따르는 아미노케톤 유도체 또는 그의 생리학적으로 허용되는 염을 투여하는 것을 특징으로 하는, 근육의 중추계 작용성 이완 방법.
  6. 제1항에 따르는 아미노게톤 유도체 또는 그의 생리학적으로 허용되는 염을 투여하는 것을 특징으로하는, 주된 증상으로서 경련성 마비, 또는 운동 기관 질환으로 인한 동통성 근육 경련을 나타내는 질병의 치료 방법.
  7. 제1항에 따르는 아미노케톤 유도체 또는 그의 생리학적으로 허용되는 염을 투여하는 것을 특징으로 하는, 요의빈삭의 치료방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900011987A 1989-08-04 1990-08-04 아미노케톤 유도체 및 그의 용도 KR920009062B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP201410 1989-08-04
JP20141089 1989-08-04
JP201410/89 1989-08-04

Publications (2)

Publication Number Publication Date
KR910004609A true KR910004609A (ko) 1991-03-29
KR920009062B1 KR920009062B1 (ko) 1992-10-13

Family

ID=16440623

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900011987A KR920009062B1 (ko) 1989-08-04 1990-08-04 아미노케톤 유도체 및 그의 용도

Country Status (10)

Country Link
EP (1) EP0414391B1 (ko)
JP (1) JPH0625178B2 (ko)
KR (1) KR920009062B1 (ko)
CN (1) CN1040105C (ko)
AT (1) ATE119890T1 (ko)
CA (1) CA2022462A1 (ko)
DE (1) DE69017794T2 (ko)
DK (1) DK0414391T3 (ko)
FI (1) FI96856C (ko)
NO (1) NO180269C (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338857A (en) * 1989-08-04 1994-08-16 Mitsui Toatsu Chemicals Incorporated Aminoketone derivatives of 1,2-oxazole and use thereof
US5055585A (en) * 1990-02-08 1991-10-08 Mitsui Toatsu Chemicals, Incorporated Preparation process of aminoketones
US5194606A (en) * 1990-02-08 1993-03-16 Mitsui Toatsu Chemicals, Incorporated Preparation process of aminoketones
JP3164631B2 (ja) * 1991-02-26 2001-05-08 三井化学株式会社 光学活性アミノケトン誘導体及びその製造法
WO1996010567A1 (fr) * 1994-09-30 1996-04-11 Maruho Co., Ltd. Derive d'aminocetone et sel physiologiquement acceptable de celle-ci et leur utilisation
US5693804A (en) * 1994-11-17 1997-12-02 Molecular Geriatrics Corporation Substituted 1-aryl-3-piperazin-1'-yl propanones
US6214994B1 (en) 1997-04-21 2001-04-10 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1′-yl propanones
DE10240026A1 (de) * 2002-08-27 2004-03-11 Merck Patent Gmbh Verfahren zur Herstellung von Monoalkylaminoketonen
JP3789465B1 (ja) 2005-04-28 2006-06-21 学校法人立教学院 イソオキサゾール誘導体又はジヒドロイソオキサゾール誘導体の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE307581B (ko) * 1963-07-31 1969-01-13 Shionogi & Co
JPS5862169A (ja) * 1981-10-09 1983-04-13 Nippon Kayaku Co Ltd 新規な５−アミノイソオキサゾ−ル誘導体
JPS58201770A (ja) * 1982-05-18 1983-11-24 Dainippon Pharmaceut Co Ltd α−置換−１，２−ベンズイソキサゾ−ル−３−酢酸エステル類並びにその酸付加塩類及び第４級アンモニウム塩類
JPS59181267A (ja) * 1983-03-30 1984-10-15 Nippon Kayaku Co Ltd 新規な５−メチルアミノ−３−置換フエニルイソオキサゾ−ル誘導体
AU4261285A (en) * 1984-06-01 1985-12-05 Tokyo Tanabe Company Limited 1-propanone derivatives
JPH0637389B2 (ja) * 1986-12-26 1994-05-18 北陸製薬株式会社 頻尿治療剤
US4980365A (en) * 1987-07-13 1990-12-25 Hoechst-Roussel Pharmaceuticals Inc. N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
IE62276B1 (en) * 1988-03-30 1995-01-25 Sankyo Co "New isoxazole derivatives for use as cerebro-active drugs and central muscle relaxants"

Also Published As

Publication number Publication date
JPH0625178B2 (ja) 1994-04-06
DE69017794T2 (de) 1995-08-03
KR920009062B1 (ko) 1992-10-13
FI903833A0 (fi) 1990-08-01
DE69017794D1 (de) 1995-04-20
EP0414391B1 (en) 1995-03-15
CN1049660A (zh) 1991-03-06
CN1040105C (zh) 1998-10-07
ATE119890T1 (de) 1995-04-15
NO180269C (no) 1997-03-19
FI96856B (fi) 1996-05-31
JPH03157375A (ja) 1991-07-05
NO903430D0 (no) 1990-08-03
AU615621B2 (en) 1991-10-03
NO180269B (no) 1996-12-09
AU5998790A (en) 1991-02-07
EP0414391A3 (en) 1991-07-17
DK0414391T3 (da) 1995-04-03
FI96856C (fi) 1996-09-10
EP0414391A2 (en) 1991-02-27
CA2022462A1 (en) 1991-02-05
NO903430L (no) 1991-02-05

Similar Documents

Publication Publication Date Title
KR900014367A (ko) 피롤리딘 유도체
BR0308816A (pt) Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas
RU2006144069A (ru) Режим приема контрацептива с антагонистом рецептора прогестерона и набор для приема
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
RU2000131183A (ru) Производные оксииминоалкановой кислоты
ATE63914T1 (de) N6-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel.
AR045040A1 (es) Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos
KR950010892A (ko) 자궁 섬유증 억제 방법
KR910004609A (ko) 아미노케톤 유도체 및 그의 용도
KR920701178A (ko) 3-아릴옥사졸리디논 유도체, 그의 제조방법 및 그의 치료 용도
ES2051834T3 (es) El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad.
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
KR900018091A (ko) 진경제
KR880005927A (ko) 카복실산 아미드의 용도
RU2005100761A (ru) Амидзамещенные производные ксантина, обладающие модуляторной активностью в отношении биосинтеза глюкозы из неуглеводных субстратов
KR880012586A (ko) 새로운 피리딜 및 피리미딜 유도체
KR880007462A (ko) 빈뇨치료용 프로피오페논 유도체
KR910011807A (ko) 4-벤질-5-페닐-2,4-디히드로-3h-1,2,4-트리아졸-3-온 및 진경제로서의 그 의 용도
KR890012942A (ko) 5-치환된 오르니틴 유도체
KR880004810A (ko) 소화성 궤양 치료제
KR950702522A (ko) 약리학적으로 활성인 α-[t-아미노메틸]벤젠메탄올 유도체(PHARMACOLOGICALLY ACTIVE α-[TERTIARY-AMINOMETHYL]-BENENEMETHANOL DERIATIVES)
ATA226688A (de) Neue thienyloxy-alkylamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
KR910002818A (ko) 4,5,6,7-사치환된 벤즈옥사졸론
KR950011446A (ko) 인돌 유도체, 그의 염 및 이를 함유하는 심질환 치료제
KR900014339A (ko) 헤테로시클릭 화합물, 그의 제조방법, 이를 함유하는 제약 조성물 및 의약으로서의 용도

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19981001

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee